TY  - GEN
AU  - Nanishi,Etsuro
AU  - Nishio,Hisanori
AU  - Takada,Hidetoshi
AU  - Yamamura,Kenichiro
AU  - Fukazawa,Mitsuharu
AU  - Furuno,Kenji
AU  - Mizuno,Yumi
AU  - Saigo,Kenjiro
AU  - Kadoya,Ryo
AU  - Ohbuchi,Noriko
AU  - Onoe,Yasuhiro
AU  - Yamashita,Hironori
AU  - Nakayama,Hideki
AU  - Hara,Takuya
AU  - Ohno,Takuro
AU  - Takahashi,Yasuhiko
AU  - Hatae,Ken
AU  - Harada,Tatsuo
AU  - Shimose,Takayuki
AU  - Kishimoto,Junji
AU  - Ohga,Shouichi
AU  - Hara,Toshiro
TI  - Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study
SN  - 2047-9980
PY  - 2018///0516
KW  - Adolescent
KW  - Anti-Bacterial Agents
KW  - adverse effects
KW  - Bacteriological Techniques
KW  - Biofilms
KW  - drug effects
KW  - Child
KW  - Child, Preschool
KW  - Clarithromycin
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Immunity, Innate
KW  - Immunoglobulins, Intravenous
KW  - Immunologic Factors
KW  - Infant
KW  - Japan
KW  - Length of Stay
KW  - Male
KW  - Mucocutaneous Lymph Node Syndrome
KW  - diagnosis
KW  - Multiplex Polymerase Chain Reaction
KW  - Recurrence
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1161/JAHA.116.005370
ER  -